Dorian is Head of Patents Pharma & Consumer Health for the Bayer group. In this position he is globally responsible for all patent matters of the Pharma and Consumer Health divisions of Bayer. His main office is in Monheim, further sites of the patent group are in Berlin, Whippany, Pittsburgh and Berkeley.

Dorian received his PhD in biochemistry from the University of Bochum in 1999 and joined Bayer to work in the Central Research facility in Leverkusen, mostly on topics around proteomics. He then moved on to pharmaceutical research in Wuppertal, before making the move to the IP world. At that time he joined the crop protection business of Bayer, where he also received his qualification as a European Patent. He was responsible for the global Environmental Science business (covering uses of pesticides outside agrochemistry). He then headed the pesticide patent group within crop protection before taking over his current role in 2010.

At MSD he has held positions as a patent lawyer handling worldwide patent litigation for various products, as a transaction attorney supporting the licensing and business development group at MSD and, in the IP group, coordinating and supervising the patent support for the licensing group and business development group.

He has a BS in molecular biology from the Massachusetts Institute of Technology and a JD from Rutgers Law School-Newark. He is admitted to practice law in New York and New Jersey.

Andrew Jenner is Director General of Interpat – a global trade association of Chief IP Counsels from the biopharmaceutical industry that seeks create sustainable innovation ecosystems to advance human health. He has a passion for collaboration and finding solutions that work in both the short and long term. He is also the Executive Director of a global strategy and policy consultancy based in the UK and assists a range of clients on corporate affairs strategies, particularly in advancing economies.

He was previous the Executive Director of Corporate Strategy and Legal Affairs at the International Federation of Pharmaceutical Manufactures and Associations (IFPMA) based in Geneva, where he deputised for the Director General. His main responsibilities included developing pharmaceutical industry strategy and policy development on priority issues. He also represented the industry within the UN and the World Trade Organization, leading a diverse team of policy, public affairs and legal professionals.

From 2007 to 2009 he was a Senior Policy Advisor and Head of the IP Crime Policy Group for the UK Intellectual Property Office (IPO), and led on the creation and implementation of an interagency strategy to combat counterfeiting and piracy.

From 2004 to 2007 he was Head of Trade & Development at the IPO and led the UK delegation within the World Trade Organization and the World Intellectual Property Organization. He was also the principle IP advisor to the EU on the World Health Organization’s negotiations on Public Health, Innovation and IP. He also led on policy relating to EU/UK IP pharmaceutical regulations, including the EU Regulation on the compulsory licensing, and implementation of the EU Human Medicines and Paediatric Medicines Regulations into UK law. He first joined the UK Government in 1998 as a patent examiner in medical and optical devices having previously worked in the automotive industry.

He is Chartered Manager (CMGR), a Fellow of the Chartered Institute of Management (FCMI), a Fellow the Royal Society of Arts (FRSA) and a Member of the Institute of Engineering & Technology (MIET) having a bachelor’s degree (B.Eng (Hons)) in Mechanical Engineering, and a Post-graduate (PgD) and Master (LLM) degrees in Law.

Robert Stanley is the Global Head of Intellectual Property for the Novartis Group, responsible for all IP matters throughout the business, as a member of Novartis’s Legal Leadership Team and head of the IP Leadership Team. He joined Novartis in 2017 as the Global Head IP Litigation. Prior to joining Novartis, Robert was a Partner at Finnegan, Henderson, Farabow, Garrett & Dunner in Atlanta, Georgia, where he focused on pharmaceutical patent litigation as well as prosecution and counseling for patents and trademarks. Robert has a B.S. in chemistry and a B.A. in political science from Furman University in Greenville, South Carolina, and a J.D. cum laude from the University of Georgia.